Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy
- First Online:
- 60 Downloads
MA17 was a randomised placebo-controlled trial of letrozole 2.5 mg/day in 5187 estrogen receptor-positive, 50% node-negative, postmenopausal women (median age 62 years at enrolment) with early breast cancer, post-5 years’ adjuvant tamoxifen therapy. The objective of this evaluation was to extrapolate the findings from the MA17 trial to estimate the lifetime cost effectiveness of letrozole in this setting.
A Markov model was used to estimate the incremental cost per QALY gained with extended adjuvant letrozole versus no therapy. Probabilities of disease progression and death were estimated using data from the MA17 study and other secondary sources. Costs of breast cancer care (letrozole therapy, surveillance, recurrences, terminal care) and treatment of osteoporosis and utilities were derived from literature. A full probabilistic sensitivity analysis was undertaken. The analysis was conducted from the perspective of the UK National Health Service (NHS) and cost estimates reflect 2004 values. All costs and outcomes were discounted at 3.5%.
Extended adjuvant letrozole resulted in a gain of 0.36 QALYs per patient (13.66 vs 13.30 with no therapy). These benefits were obtained at an additional expected lifetime cost of £3732 per patient (£10 833 letrozole vs £7101 with no therapy). Cost effectiveness was estimated at £10 338 per QALY gained (95% CI 5276, 43 828). The results were robust to sensitivity analyses.
Five years of letrozole therapy appears to be cost effective from the NHS perspective and should be considered in women with early breast cancer, following tamoxifen adjuvant therapy.
- 1.Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia (PA): JB Lippencott Co., 1993Google Scholar
- 2.Glick JH. Adjuvant therapy for node-negative breast cancer. In: Fowble B, Goodman, RL, Glick JH, et al. Breast cancer treatment: a comprehensive guide to management. St Louis (MO): Mosby Year Book, 1991Google Scholar
- 6.Goss P, Ingle IN, Marino S, et al. Updated analysis of the NCIC CTG MA-17 randomized placebo controlled trial of letrozole after five years of tamoxifen in postmenopausal women with early stage breast cancer [abstract 847]. Proc Am Soc Clin Oncol; 2004 Jun 5–8; New OrleansGoogle Scholar
- 15.Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19 (10): 2596–2606PubMedGoogle Scholar
- 18.NHS Executive. The new NHS 2002 reference costs. London: Department of Health, 2002Google Scholar
- 19.Netten A, Curtis L. Unit costs of health and social care, PSSRU. Kent: University of Kent, 2003Google Scholar
- 21.Sorensen S, Brown R, Benedict A, et al. Patient-rated utilities in postmenopausal early breast cancer: a cross country comparison. ISPOR Seventh Annual European Congress; 2004 Oct 24–26; HamburgGoogle Scholar
- 22.Interim life tables for England and Wales 1999–2001. Actuary’ s Department. UK Government [online]. Available from URL: http://www.gad.gov.uk/Life_Tables/Historical_Interim_life_tables.htm [Accessed 2006 Feb 5]
- 24.National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004 AprGoogle Scholar